Swedencare Valuation

Q: What is the Fair Price of SWDC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SWDC.F ($4.25) is trading below our estimate of [[fair value]] ($15.09)

Is SWDC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SWDC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWDC.F ($4.25) is trading below our estimate of fair value ($15.09)

Significantly Below Fair Value: SWDC.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWDC.F?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SWDC.F. This is calculated by dividing SWDC.F's market cap by their current preferred multiple.
What is SWDC.F's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 6.89b

SWDC.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.4x
Enterprise Value/EBITDA	16.3x
PEG Ratio	1.6x

Price to Earnings Ratio vs Peers

How does SWDC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SWDC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	21.9x
ANIP ANI Pharmaceuticals	50x	35.4%	US$1.1b
PCRX Pacira BioSciences	10.5x	27.2%	US$661.0m
ELTP Elite Pharmaceuticals	21.3x	n/a	US$415.5m
SIGA SIGA Technologies	5.9x	n/a	US$495.3m
SWDC.F Swedencare	90.6x	56.1%	US$6.9b

Price-To-Earnings vs Peers: SWDC.F is expensive based on its Price-To-Earnings Ratio (90.6x) compared to the peer average (21.9x).

Price to Earnings Ratio vs Industry

How does SWDC.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.7%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: SWDC.F is expensive based on its Price-To-Earnings Ratio (90.6x) compared to the US Pharmaceuticals industry average (19.2x).

Price to Earnings Ratio vs Fair Ratio

What is SWDC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWDC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	90.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SWDC.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SWDC.F forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$4.25	US$5.82 +37.0%	1.6%	US$5.91	US$5.73	n/a	2
Sep ’25	n/a	US$5.82 0%	1.6%	US$5.91	US$5.73	n/a	2
Aug ’25	n/a	US$5.82 0%	1.6%	US$5.91	US$5.73	n/a	2
Jul ’25	n/a	US$6.13 0%	4.5%	US$6.40	US$5.85	n/a	2
Jun ’25	n/a	US$6.13 0%	4.5%	US$6.40	US$5.85	n/a	2
May ’25	US$5.11	US$6.13 +19.9%	4.5%	US$6.40	US$5.85	n/a	2
Apr ’25	US$6.05	US$6.52 +7.8%	5.9%	US$6.90	US$6.13	n/a	2
Mar ’25	n/a	US$6.52 0%	5.9%	US$6.90	US$6.13	n/a	2
Feb ’25	n/a	US$5.80 0%	7.6%	US$6.24	US$5.36	n/a	2
Jan ’25	n/a	US$4.48 0%	10.0%	US$4.92	US$4.03	n/a	2
Dec ’24	n/a	US$4.48 0%	10.0%	US$4.92	US$4.03	n/a	2
Nov ’24	n/a	US$4.48 0%	10.0%	US$4.92	US$4.03	n/a	2
Oct ’24	US$3.71	US$4.51 +21.4%	9.1%	US$4.92	US$4.10	n/a	2
Sep ’24	n/a	US$4.51 0%	9.1%	US$4.92	US$4.10	n/a	2
Aug ’24	n/a	US$4.22 0%	21.3%	US$5.12	US$3.32	n/a	2
Jul ’24	n/a	US$4.11 0%	21.3%	US$4.99	US$3.23	n/a	2
Jun ’24	n/a	US$4.11 0%	21.3%	US$4.99	US$3.23	n/a	2
May ’24	US$2.60	US$4.09 +57.5%	31.0%	US$5.36	US$2.83	US$5.11	2
Apr ’24	n/a	US$4.48 0%	26.3%	US$5.66	US$3.30	US$6.05	2
Mar ’24	US$2.76	US$4.52 +63.9%	27.0%	US$5.74	US$3.30	n/a	2
Feb ’24	US$3.19	US$5.23 +64.0%	37.0%	US$7.17	US$3.30	n/a	2
Jan ’24	US$2.98	US$5.52 +85.7%	29.3%	US$7.14	US$3.91	n/a	2
Dec ’23	n/a	US$5.52 0%	29.3%	US$7.14	US$3.91	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.